Skip to main content

Table 5 Sensitivity analyses for association between low-dose aspirin use and cancer-specific mortality in lung cancer patients

From: Low-dose aspirin and survival from lung cancer: a population-based cohort study

  Cancer-specific deaths All patients Person years Unadjusted P Adjusteda P
     HR 95 % CI   HR 95 % CI  
Main analysis: Pre-diagnostic aspirin useb 10,632 13,433 12,485 1.07 1.02, 1.11 <0.01 1.00 0.95, 1.05 0.91
Subgroup analyses          
 Male 6,298 7,941 7,103 1.02 0.97, 1.08 0.44 0.98 0.91–1.04 0.46
 Female 4,334 5,492 5,381 1.13 1.06–1.21 <0.001 1.03 0.95–1.11 0.53
Sensitivity analyses          
 Smoking prior to diagnosis available (and adjusted for) 9,560 12,063 11,336 1.07 1.03–1.12 <0.01 1.00 0.95–1.05 0.93
 BMI prior to diagnosis available (and adjusted for) 8,562 10,831 10,448 1.07 1.02–1.12 <0.01 0.99 0.94–1.05 0.73
 Aspirin use between 2 years and 6 months prior to diagnosisc 9,746 12,295 11,418 1.06 1.01–1.11 0.01 0.99 0.94–1.05 0.76
  1. aExcept where otherwise stated, adjusted for year of diagnosis, age at diagnosis, gender, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other medication use (in year prior to diagnosis, specifically statins and beta-blockers) and deprivation (in fifths)
  2. bBased upon use in the year prior to diagnosis, restricted to individuals with 1 year of records prior to lung cancer diagnosis
  3. cRestricted to individuals with 2 years of records prior to diagnosis, removing prescriptions in the 6 months prior to lung cancer diagnosis as these could reflect increased medical care due to early symptoms
\